Iclusig
| Iclusig | |
|---|---|
| Term | Iclusig |
| Short definition | Iclusig (i-KLOO-sig) A drug used to treat adults with certain types of chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia. It is used in patients whose cancer has the T315I mutation or whose cancer cannot be treated with other tyrosine kinase inhibitors. |
| Type | Cancer terms |
| Specialty | Oncology |
| Language | English |
| Source | NCI |
| Comments | |
Iclusig - (pronounced) (i-KLOO-sig) A drug used to treat adults with certain types of chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia. It is used in patients whose cancer has the T315I mutation or whose cancer cannot be treated with other tyrosine kinase inhibitors. It is also being studied in the treatment of other types of cancer. Iclusig blocks BCR-ABL and other proteins that can help prevent cancer cells from growing and kill them. It can also prevent the growth of new blood vessels that tumors need to grow. Iclusig is a type of tyrosine kinase inhibitor and a type of anti-angiogenesis agent. Also called ponatinib hydrochloride
External links
- Medical encyclopedia article on Iclusig
- Wikipedia's article - Iclusig
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski